Research & Development Market Research Reports & Industry Analysis
New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.
Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.
Research & Development Industry Research & Market Reports
-
Rheumatoid Arthritis Therapeutics
... at a CAGR of 4.1% over the analysis period 2024-2030. Pharmaceuticals, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$28.0 Billion by the end of the ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Male Hypogonadism
... CAGR of 5.1% over the analysis period 2024-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the ... Read More
-
Medical Marijuana
... CAGR of 14.4% over the analysis period 2024-2030. Extract Form, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$60.5 Billion by the end of the analysis ... Read More
-
Marijuana Drying and Curing Equipment
... Million by 2030, growing at a CAGR of 9.5% over the analysis period 2024-2030. The U.S. Market is Estimated at US$55.2 Million While China is Forecast to Grow at 8.7% CAGR The Marijuana Drying and ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the analysis ... Read More
-
CBD Gummies
... CAGR of 28.8% over the analysis period 2024-2030. Low, one of the segments analyzed in the report, is expected to record a 28.2% CAGR and reach US$32.4 Billion by the end of the analysis period. ... Read More
-
Contract Research Organization Services (CROs)
... Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Clinical Research, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$76.7 Billion ... Read More
-
In Vivo Toxicology
... at a CAGR of 6.4% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$6.8 Billion by the end of the ... Read More
-
Cannabis Drinks Market Size, Share, and Outlook, 2025 Report- By Type (Cannabis Infused Wine, Cannabis-Infused Beer, Cannabis Infused Water, Cannabis Infused Coffee, Cannabis Infused Tea, Cannabis Infused Juice, Others), Flavor (UnFlavored, Fruit, Apple Cider, Black Tea, Cappuccino, Caramel), Component (Tetrahydrocannabinol (THC) Infused Drinks, Cannabidiol (CBD) Infused Drinks, Others), Distribution Channel (Supermarkets and Hypermarkets, Convenience stores, Specialty stores, Online), and Companies, 2021-2032
... market is a thriving business that is poised to keep growing and presents potential growth opportunities for companies across the industry value chain. The comprehensive market research report presents 12-year historic and forecast data on ... Read More
-
Cannabis Pharmaceuticals
... CAGR of 55.1% over the analysis period 2024-2030. Sativex Brand, one of the segments analyzed in the report, is expected to record a 60.1% CAGR and reach US$52.6 Billion by the end of the analysis ... Read More
-
Dry Herb Cannabis Vaporizers
... 2030, growing at a CAGR of 15.2% over the analysis period 2024-2030. Tabletop, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$10.0 Billion by the end ... Read More
-
Neurodegenerative Drugs
... CAGR of 6.8% over the analysis period 2024-2030. Dopamine Agonist, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.7 Billion by the end of the analysis ... Read More
-
Fibromyalgia Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Antiepileptics, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. ... Read More
-
Antibacterial Drugs
... CAGR of 3.8% over the analysis period 2024-2030. ß-lactams, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
HIV Drugs
... CAGR of 5.2% over the analysis period 2024-2030. Combination HIV Medicines, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$29.0 Billion by the end of the ... Read More
-
Cancer Immunotherapy
... CAGR of 13.7% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$266.2 Billion by the end of the analysis ... Read More
-
Quantum Computing in Healthcare
... 2030, growing at a CAGR of 36.9% over the analysis period 2024-2030. Services, one of the segments analyzed in the report, is expected to record a 40.1% CAGR and reach US$452.4 Million by the end ... Read More
-
Preclinical Contract Research Organizations
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Toxicology Testing, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$3.2 Billion by the ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC), one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by the ... Read More
-
Acne Drugs
... CAGR of 6.9% over the analysis period 2024-2030. Inflammatory, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$9.6 Billion by the end of the analysis period. ... Read More
-
Cannabis Beverages
... CAGR of 16.3% over the analysis period 2024-2030. Non-Alcoholic Beverage, one of the segments analyzed in the report, is expected to record a 16.8% CAGR and reach US$2.1 Billion by the end of the analysis ... Read More
-
Cannabis Extract
... CAGR of 15.6% over the analysis period 2024-2030. Oils, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$34.1 Billion by the end of the analysis period. ... Read More
-
CBD Nutraceuticals
... CAGR of 18.1% over the analysis period 2024-2030. CBD Tinctures, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$11.9 Billion by the end of the analysis ... Read More
-
Pancreatic Cancer Drugs
... at a CAGR of 4.6% over the analysis period 2024-2030. Exocrine, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$3.2 Billion by the end of the ... Read More
Research Assistance
